Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

PRESS RELEASE

Cordlife Named As Runner-Up In The Mid And Small Category Of The 16th SIAS Investors' Choice Awards - Singapore Corporate Governance Award 2015

Singapore, 16 October 2015 – Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), a mother and child consumer healthcare company, announced today that it was named as the Runner-up of the 16th SIAS Investors' Choice Award - Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category.

The SIAS Investors' Choice Awards (ICA) honours and recognizes public listed companies which have demonstrated exemplary Corporate Governance and Transparency practices throughout the year. Prior to the award this year, Cordlife was named the "Most Transparent Company 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards in November 2013. In 2012, Cordlife was also a runner-up for the same award in the New Issues Category.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said: "We are deeply honoured to be recognised for our efforts in adopting the best practices and holding ourselves up to the highest standards of corporate governance. As a market leader in the cord blood banking industry and consumer healthcare space, Cordlife understands that our business success is premised on excellence and dedication to quality service by adhering to gold standards in the industry. Similarly, it is our belief that success in our relations with the investing community is only achievable if we maintain a high level of corporate transparency. Going forward, we will continue to provide accurate and unambiguous information in a timely manner to build and maintain trust with both our shareholders and stakeholders."

The awards were presented at a dinner event held tonight at Dinner Presentation Ceremony on 16th October 2015 at Raffles City Convention Centre, Fairmont Ballroom.

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia and the Philippines[1]. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks.

Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. In October 2013, Cordlife also acquired a 19.92% stake, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad ("StemLife"). StemLife is a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy. In addition, in April 2013, Cordlife became the first private cord blood bank in Asia to have launched SEPAX®2, a Swiss-made FDA-approved, GMP compliant automated stem cell processing system that maximises automation while ensuring consistently high cell recoveries.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards Year 2013, "My Favourite Cord Blood Bank" by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader's Choice by Child Magazine; 2013-2014 MyBB Parent-Child Favorite Cord Blood and Umbilical Cord Bank Company and Baby Kingdom Top 10 Family Brand Award 2012[2]. In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, "Best Investor Relations Award". In November 2013, Cordlife was named the "Most Transparent Company 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards.

[1] Source : Deloitte & Touche Financial Advisory Services Limited report, October 2014
[2] Awarded to Cordlife (Hong Kong) Limited

ISSUED ON BEHALF OF	:	Cordlife Group Limited
BY	:	Financial PR Pte Ltd 4 Robinson Road #04-01 The House of Eden Singapore 048543
CONTACT	:	Mr Kamal Samuel / Mr Mark Lin
OFFICE	:	6438-2990
EMAIL	:	kamal@financialpr.com.sg / marklin@financialpr.com.sg